Equities

Gene therapy comes of age

Oxford BioMedica may have a cure for leukaemia. Its share price has soared since the last week of June. Its…

Was Woodford right to sell Glaxo and hold AstraZeneca?

AstraZeneca (LON:AZN) and GlaxoSmithKline (LON:GSK) are the two pharmaceutical giants of the FTSE 100. They are also both high yield…

2 of the best UK-focused recovery stocks

Recovery stocks can be among the most profitable investments. One reason for this is that the market usually expects disappointing…

3 ways to capitalise on UK housing potential

The housing market has been a profitable place to invest in the last few decades. A fundamental imbalance between supply…

How to profit from the aviation revolution

Things are changing in the aviation business. Three new trends in aircraft technology are about to revolutionise the industry. First,…

The forthcoming global cyber-war – and who will win

On 12 May this year a virulent piece of ransomware was unleashed upon the globe by persons yet unknown. In…

3 of the highest-yielding FTSE 100 shares

One of the major challenges facing investors is how to generate an income return which beats inflation. This has been…

Are these the top 3 gold stocks in London?

Gold may not have a practical value as an alternative currency. It’s not possible to enter a shop and pay…

The ONE ratio that reveals how expensive tech stocks really are

- FANG Stocks (Facebook, Amazon, Netflix, Google/Alphabet) have rallied a few times in the last 4-5 years. This seems to…

Weakening pound makes Vodafone more attractive

Since the EU referendum on 23 June 2016, the pound has weakened significantly versus a basket of major currencies. For…